ResearchWorks Archive

World Antimalarial Resistance Network (WARN) II: In vitro antimalarial drug susceptibility

Show simple item record Bacon, David J. en_US Jambou, Ronan en_US Fandeur, Thierry en_US Le Bras, Jacques en_US Wongsrichanalai, Chansuda en_US Fukuda, Mark M. en_US Ringwald, Pascal en_US Sibley, Carol Hopkins en_US Kyle, Dennis E. en_US 2010-05-06T20:05:55Z 2010-05-06T20:05:55Z 2007 en_US
dc.identifier.citation Bacon D, Jambou R, Fandeur T, et al. World Antimalarial Resistance Network (WARN) II: In vitro antimalarial drug susceptibility. Malaria Journal. 2007;6(1):120. en_US
dc.identifier.other 10.1186/1475-2875-6-120 en_US
dc.identifier.uri en_US
dc.description.abstract Intrinsic resistance of Plasmodium falciparum is clearly a major determinant of the clinical failure of antimalarial drugs. However, complex interactions between the host, the parasite and the drug obscure the ability to define parasite drug resistance in vivo. The in vitro antimalarial drug susceptibility assay determines ex-vivo growth of parasite in the presence of serial drug concentrations and, thus, eliminates host effects, such as drug metabolism and immunity. Although the sensitivity of the parasite to various antimalarials provided by such a test provides an important indicator of intrinsic parasite susceptibility, there are fundamental methodological issues that undermine comparison of in vitro susceptibility both between laboratories and within a single laboratory over time. A network of laboratories is proposed that will agree on the basic parameters of the in vitro test and associated measures of quality control. The aim of the network would be to establish baseline values of sensitivity to commonly used antimalarial agents from key regions of the world, and create a global database, linked to clinical, molecular and pharmacology databases, to support active surveillance to monitor temporal trends in parasite susceptibility. Such a network would facilitate the rapid detection of strains with novel antimalarial resistance profiles and investigate suitable alternative treatments with retained efficacy. en_US
dc.description.sponsorship Some of this work was supported by funds provided by the Department of Defense-Global Emerging Infectious System (DoD-GEIS) under the unit number 847705.82000.256B, B0016. en_US
dc.language.iso en_US en_US
dc.title World Antimalarial Resistance Network (WARN) II: In vitro antimalarial drug susceptibility en_US
dc.type Article en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search ResearchWorks

Advanced Search


My Account